TransMedics Group, Inc. $TMDX Holdings Increased by WINTON GROUP Ltd

WINTON GROUP Ltd lifted its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 52.4% in the second quarter, HoldingsChannel reports. The fund owned 18,203 shares of the company’s stock after purchasing an additional 6,262 shares during the quarter. WINTON GROUP Ltd’s holdings in TransMedics Group were worth $1,209,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Royal Bank of Canada raised its holdings in TransMedics Group by 47.9% during the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after purchasing an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in TransMedics Group by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after purchasing an additional 868 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after purchasing an additional 86,721 shares during the period. Russell Investments Group Ltd. increased its position in shares of TransMedics Group by 13.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after purchasing an additional 938 shares during the period. Finally, M&T Bank Corp bought a new stake in shares of TransMedics Group in the 2nd quarter worth $209,000. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Price Performance

TMDX stock opened at $82.18 on Monday. TransMedics Group, Inc. has a one year low of $60.10 and a one year high of $156.00. The firm has a 50-day moving average of $82.00 and a two-hundred day moving average of $90.26. The firm has a market capitalization of $2.84 billion, a PE ratio of 21.13, a P/E/G ratio of 1.13 and a beta of 1.90. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. During the same period last year, the business earned $0.92 earnings per share. The business’s revenue was up 20.7% on a year-over-year basis. On average, analysts forecast that TransMedics Group, Inc. will post 1.46 earnings per share for the current year.

Wall Street Analyst Weigh In

TMDX has been the subject of several research analyst reports. Piper Sandler restated an “overweight” rating and issued a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. TD Cowen reaffirmed a “buy” rating and set a $120.00 target price on shares of TransMedics Group in a report on Tuesday, September 8th. Stifel Nicolaus boosted their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, June 18th. Needham & Company LLC reissued a “buy” rating on shares of TransMedics Group in a report on Friday. Finally, UBS Group reduced their price objective on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a research report on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $124.18.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.